By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Assembly Biosciences (Formerly Known As Assembly Pharmaceuticals) 

11711 North Meridian Street
Suite 310
Indianapolis  Indiana  46032  U.S.A.
Phone: 317 210-9311 Fax: n/a


SEARCH JOBS

Assembly Biosciences, Inc. is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome. Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV by targeting core protein, an essential viral protein involved in multiple critical functions throughout the HBV lifecycle. Assembly’s core protein allosteric modifiers (CpAMs) are direct-acting antivirals that modulate core protein. Assembly’s initial CpAM, ABI-H0731, is currently in Phase 1 clinical development. The company’s microbiome program consists of a fully integrated platform that includes a robust microbial strain identification and selection process, methods for strain isolation and growth under current pharmaceutical Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates


Key Statistics


Email: info@assemblybio.com
Ownership: Public

Web Site: Assembly Biosciences
Employees: 65 full-time and 40+ contract team members
Symbol: ASMB
 



Industry
Biotechnology






Company News
Assembly Biosciences (ASMB) Announces The Closing And Early Termination Of Hart-Scott-Rodino Waiting Period For License Of Microbiome Gastrointestinal Development Programs To Allergan (AGN) 2/21/2017 8:30:28 AM
Assembly Biosciences (ASMB) Announces Successful Completion Of ABI-H0731 Phase Ia Trial And Upcoming Conference Presentations 2/16/2017 8:00:03 AM
Allergan (AGN) Enters Into Licensing Agreement With Assembly Biosciences (ASMB) To Obtain Worldwide Rights To Microbiome Gastrointestinal Development Programs 1/9/2017 7:33:28 AM
Assembly Biosciences Initiates Phase I Clinical Program Of ABI-H0731 For Treatment Of Chronic Hepatitis B Virus Infection 11/9/2016 7:26:08 AM
Assembly Biosciences Announces Key Additions To Microbiome Team 9/28/2016 7:40:03 AM
Assembly Biosciences Announces Participation In HBV Scientific Meetings In China And South Korea 9/21/2016 10:28:29 AM
Assembly Biosciences To Present At The Jefferies 2016 Global Healthcare Conference 6/1/2016 8:21:09 AM
Assembly Biosciences To Present Data At The International Liver Congress 2016 That Supports Advancing Its CpAM Candidates Into HBV Clinical Trials 4/13/2016 8:07:17 AM
Assembly Biosciences To Present Data On New Series Of HBV Core Protein Allosteric Modifiers At The International Liver Congress™ 2016 3/30/2016 10:05:57 AM
Assembly Biosciences Expands Senior Leadership Team 1/11/2016 8:31:33 AM
12
//-->